Marinomed Biotech AG · ISIN: ATMARINOMED6 · EQS - Company News

Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal

Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis Data from phase II dose-finding clinical trial have been published in peer-reviewed Clinical Ophthalmology journal Tacrosolv offers great potential in treatment ...

VIE:MARI Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Marinomed Biotech AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
08 October 2024 07:45AM
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
ATMARINOMED6
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis Data from ph...
Marinomed Biotech AG
About the publication
24 September 2024 07:45AM
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
ATMARINOMED6
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54% Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced Eye drops hold ...
Marinomed Biotech AG
About the publication
24 September 2024 07:45AM
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
ATMARINOMED6
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops Marinomeds new Carragelose eye drops improve dry eye-related symptoms in patients with mild to moderate dry eye syndrome by remarkable 54% Product was well tolerated by patients and ocular surface disease index (OSDI) was significantly reduced Eye drops hold ...
Marinomed Biotech AG
About the publication
18 September 2024 05:21PM
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
ATMARINOMED6
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and...
Marinomed Biotech AG
About the publication
18 September 2024 05:21PM
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
ATMARINOMED6
Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board has resolved today to increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by issuing 154,053 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024 and...
Marinomed Biotech AG
About the publication
15 September 2024 05:49PM
Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights
ATMARINOMED6
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th...
Marinomed Biotech AG
About the publication
15 September 2024 05:49PM
Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights
ATMARINOMED6
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the “Company”) announces that today the Management Board decided to set a price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a potential capital increase of up to 154,053 new shares to be issued under the Authorized Capital 2024 and subject to the direct exclusion of th...
Marinomed Biotech AG
About the publication
11 September 2024 07:45AM
First Carragelose products receive new Medical Device Regulation (MDR) certification
ATMARINOMED6
Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification Two Carragelose nasal sprays have received declaration of conformity under the new medical device regulation - certificates for further products expected later in the year Extensive clinical data for Carragelose facilitates challenging deman...
Marinomed Biotech AG
About the publication
02 September 2024 05:46PM
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
ATMARINOMED6
Korneuburg, Austria, 02. September 2024 - Marinomed Biotech AG (the “Company”) announces that the Management Board decided today to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the direct exclusion of statutory subscription rights of existing shareholders, to finance the ongoing c...
Marinomed Biotech AG
About the publication
20 August 2024 06:00PM
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
ATMARINOMED6
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024 Revenues of EUR 2.5 million generated in the first half of 2024 (H1 2023: EUR 5.2 million); cash and cash equivalents as of 30.06.2024 at EUR 0.9 million (31.12.2023: EUR 2.6 million) Court restructuring proceedings without self-administration opened on August 1...
Marinomed Biotech AG
About the publication
14 August 2024 03:35PM
Court opens restructuring proceedings without self-administration
ATMARINOMED6
Korneuburg, Austria, 14. August 2024 – Marinomed Biotech AG (VSE:MARI) announces that on August 14, 2024, the Regional Court of Korneuburg opened restructuring proceedings without self-administration at the request of Marinomed Biotech AG. The Company expects trading of Marinomed shares to resume soon and a switch to the standard market continuous ...
Marinomed Biotech AG
About the publication
14 August 2024 09:17AM
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
ATMARINOMED6
 Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration Application for opening of restructuring proceedings Funds necessary to secure liquidity could not be raised as planned This step is intended to ensure the Company's continued existence in the long term in agreement with its creditors...
Marinomed Biotech AG
About the publication
13 August 2024 11:04PM
Marinomed Biotech AG applies for court restructuring proceedings without self-administration
ATMARINOMED6
Korneuburg, Austria, 13. August 2024 – Marinomed Biotech AG (VSE:MARI) announces to apply for the initiation of court restructuring proceedings. The aim is to carry out restructuring proceedings without self-administration. As a result of the inability to raise funds required at short notice to secure the Company’s liquidity, insolvency is imminent...
Marinomed Biotech AG
About the publication
14 June 2024 07:45AM
Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe
ATMARINOMED6
Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe Marinomed signs an additional licensing agreement with an existing partner for the distribution and marketing of Carragelose® products in Europe and selected other countries Marinomed eligible to receive mileston...
Marinomed Biotech AG
About the publication
22 May 2024 07:45AM
Marinomed Biotech AG announces results for the first quarter of 2024
ATMARINOMED6
Marinomed Biotech AG announces results for the first quarter of 2024 Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality Q1 2024: New partnerships for Carragelose and Solv4U, agreement with financing partners for deferral of repayments and progress w...
Marinomed Biotech AG
About the publication
25 April 2024 07:45AM
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
ATMARINOMED6
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed will apply the Marinosolv solubilization technology to improve target compounds with the goal of developing products with differentiated pharmacological profiles The project covers the proof-of-concept evaluation and future d...
Marinomed Biotech AG
About the publication
16 April 2024 07:45AM
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
ATMARINOMED6
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record years (2022: EUR 11.3 million) Important progress for Carragelose with new distribution partners and new products as well as Marinosolv ...
Marinomed Biotech AG
About the publication
11 April 2024 07:45AM
Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
ATMARINOMED6
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infectio...
Marinomed Biotech AG
About the publication
28 March 2024 07:45AM
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
ATMARINOMED6
 Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months Agreement with the EIB provides for a deferral of all capital repayments for 18 months, while interest rates remain unchanged Real estate lenders also agreed to suspend repayments for 18 months Marinomed plans ...
Marinomed Biotech AG
About the publication
26 March 2024 07:45AM
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
ATMARINOMED6
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG...
Marinomed Biotech AG
About the publication
26 March 2024 07:45AM
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
ATMARINOMED6
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe Gulf-region specialist GAIA Healthcare FZ LLC obtains license for the marketing of Carragelose nasal sprays Expansion of Carragelose partner network in Eastern Europe with VitaPlus Kft. Korneuburg, Austria, 26 March 2024 – Marinomed Biotech AG...
Marinomed Biotech AG
About the publication
01 March 2024 07:45AM
Lucia Ziegler new Head of Investor & Public Relations
ATMARINOMED6
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations Korneuburg, Austria, 1 March 2024 – Lucia Ziegler will take over the newly integrated "Investor & Public Relations" department at Marinomed Biotech AG (VSE:MARI) as of the beginning of March 2024. In addition to her previous PR tasks, Lucia Ziegler will also be res...
Marinomed Biotech AG
About the publication
14 February 2024 07:45AM
Marinomed Biotech AG announces preliminary revenue for 2023
ATMARINOMED6
 Marinomed Biotech AG announces preliminary revenue for 2023 Preliminary revenues eased as expected to € 9.2 m in 2023 (2022: € 11.3 m) due to reduced Carragelose order volumes caused by sufficient customer stock levels Cash position at € 2.6 m; financial stability secured by cost-conscious cash management and convertible note funding program O...
Marinomed Biotech AG
About the publication
07 February 2024 07:45AM
Marinomed Biotech AG with important progress for Carragelose in 2024
ATMARINOMED6
Marinomed Biotech AG with important progress for Carragelose in 2024 First patient enrolled in clinical study investigating the moisturizing effectiveness of Carragelose eye drops Clinical data showing the effectiveness of Carragelose in alleviating allergic symptoms in patients with grass pollen allergy published in peer-reviewed International J...
Marinomed Biotech AG
About the publication
18 December 2023 08:33AM
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
ATMARINOMED6
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio Marinomed evaluates strategic options for Carragelose business and hires advisor to approach potential partners Change in regulatory legislation for medical devices creates favourable market environment for Carragelose product portfolio Marinomed to focus on core competen...
Marinomed Biotech AG
About the publication
18 December 2023 08:30AM
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
ATMARINOMED6
Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) announces that the Company considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. The Company is continuously evaluating ...
Marinomed Biotech AG
About the publication
14 December 2023 07:45AM
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent
ATMARINOMED6
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent Marinomed has entered into a new distribution partnership with Favorex Ptd Ltd, a subsidiary of DKSH, for distributing a Carragelose nasal spray in Southeast Asia EU patent office granted “Notice of allowance” for protecting the use of carrageenans for...
Marinomed Biotech AG
About the publication
21 November 2023 07:45AM
Stable revenues in the first three quarters of 2023 and further progress in business development
ATMARINOMED6
Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development Q1-Q3 2023 with stable revenues of € 7.2 million (Q1-Q3 2022: € 7.1 million) Marinosolv: progress in business development for Budesolv and Tacrosolv with several interested parties Carragelose: High demand for existing virus blo...
Marinomed Biotech AG
About the publication
17 October 2023 07:45AM
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
ATMARINOMED6
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume Marinomed and Nice & Green agree to resume flexible Convertible Notes Funding Program with reduced tranches Funds will be used to secure project financing and maintain financial flexibility on the way to achieving operational profitability Korn...
Marinomed Biotech AG
About the publication
17 August 2023 07:45AM
Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
ATMARINOMED6
Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities Half-year results show revenue growth of 7% to € 5.2 million (H1 2022: € 4.9 million) Marinosolv: Business development activities for Tacrosolv and Budesolv in full force Carragelose: Successful market entry with nasal spray in M...
Marinomed Biotech AG
About the publication
09 August 2023 07:45AM
Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.
ATMARINOMED6
Marinomed enters first long-term Solv4U partnership with Shanghai-based SPH Sine Pharmaceutical Laboratories Co. Ltd. SPH Sine will use Marinomed's proprietary Marinosolv technology to dissolve its active pharmaceutical ingredient (API) in an orally inhaled and nasal drug product (OINDP) formulation The developed know-how technology of the unique...
Marinomed Biotech AG
About the publication
27 July 2023 07:45AM
M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
ATMARINOMED6
Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico Marinomeds distribution partner M8 Pharmaceuticals obtained market approval for distribution and marketing of a Carragelose nasal spray in Mexico Launch of the product under the trade name Barlo® is planned for the upcoming season Promisi...
Marinomed Biotech AG
About the publication
27 July 2023 07:45AM
Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
ATMARINOMED6
Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico Marinomeds distribution partner M8 Pharmaceuticals obtained market approval for distribution and marketing of a Carragelose nasal spray in Mexico Launch of the product under the trade name Barlo® is planned for the upcoming season Promisi...
Marinomed Biotech AG
About the publication
13 July 2023 07:45AM
Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
ATMARINOMED6
Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan Joint publication of virologists in the peer-reviewed journal Nutraceuticals demonstrates effectiveness of iota-carrageenan (Carragelose) against SARS-CoV-2 Omicron variants BA.1, ...
Marinomed Biotech AG
About the publication
13 July 2023 07:45AM
Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
ATMARINOMED6
Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan Joint publication of virologists in the peer-reviewed journal Nutraceuticals demonstrates effectiveness of iota-carrageenan (Carragelose) against SARS-CoV-2 Omicron variants BA.1, ...
Marinomed Biotech AG
About the publication
21 June 2023 05:00PM
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board
ATMARINOMED6
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board Industry expert Dr. Eva Hofstädter-Thalmann complements high-profile Supervisory Board Dr. Simon Nebel and Mag. Brigitte Ederer reappointed Current female representation on Supervisory Board reaches at 60% Korneuburg, Austria...
Marinomed Biotech AG
About the publication
21 June 2023 05:00PM
Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board
ATMARINOMED6
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board Industry expert Dr. Eva Hofstädter-Thalmann complements high-profile Supervisory Board Dr. Simon Nebel and Mag. Brigitte Ederer reappointed Current female representation on Supervisory Board reaches at 60% Korneuburg, Austria...
Marinomed Biotech AG
About the publication
15 June 2023 07:45AM
Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
ATMARINOMED6
 Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024 Moisturizing eye drops complement existing Carragelose OTC product portfolio Benefits of Carragelose extended to application in the eye Single-territory test launch in Austria in preparation for 2024 and business development process for international roll-out initiated Korneu...
Marinomed Biotech AG
About the publication
15 June 2023 07:45AM
Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
ATMARINOMED6
 Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024 Moisturizing eye drops complement existing Carragelose OTC product portfolio Benefits of Carragelose extended to application in the eye Single-territory test launch in Austria in preparation for 2024 and business development process for international roll-out initiated Korneu...
Marinomed Biotech AG
About the publication
23 May 2023 07:45AM
Marinomed Biotech AG reports best first quarter in company history
ATMARINOMED6
Marinomed Biotech AG reports best first quarter in company history Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing Marinosolv: Full focus on commercialization of product candidates Tacro...
Marinomed Biotech AG
About the publication
23 May 2023 07:45AM
Marinomed Biotech AG reports best first quarter in company history
ATMARINOMED6
Marinomed Biotech AG reports best first quarter in company history Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing Marinosolv: Full focus on commercialization of product candidates Tacro...
Marinomed Biotech AG
About the publication
19 April 2023 07:45AM
Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
ATMARINOMED6
 Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023 Carragelose revenues show double-digit growth for the fourth year in a row New growth opportunities driven by license agreement with Procter & Gamble, US patent for Marinosolv technology and expansion of Solv4U technology partnerships Outlook 2023: Movi...
Marinomed Biotech AG
About the publication
19 April 2023 07:45AM
Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
ATMARINOMED6
 Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023 Carragelose revenues show double-digit growth for the fourth year in a row New growth opportunities driven by license agreement with Procter & Gamble, US patent for Marinosolv technology and expansion of Solv4U technology partnerships Outlook 2023: Movi...
Marinomed Biotech AG
About the publication
12 April 2023 07:45AM
Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
ATMARINOMED6
Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever Carragelose nasal spray shows significant effectiveness in the prophylactic treatment of allergic rhinitis symptoms in the nose Clinical data extend the effectiveness of Carragelose from blocking respiratory viruses to p...
Marinomed Biotech AG
About the publication
12 April 2023 07:45AM
Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
ATMARINOMED6
Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever Carragelose nasal spray shows significant effectiveness in the prophylactic treatment of allergic rhinitis symptoms in the nose Clinical data extend the effectiveness of Carragelose from blocking respiratory viruses to p...
Marinomed Biotech AG
About the publication
14 March 2023 07:45AM
Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray
ATMARINOMED6
  Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray Clinical data shows a significant decongestant effect of the Sorbitol-containing Carragelose nasal spray in allergic rhinitis patients The product utilizes the effect of Sorbitol as treatment of a blocked nose without the side effect of habituation...
Marinomed Biotech AG
About the publication
14 March 2023 07:45AM
Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray
ATMARINOMED6
  Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray Clinical data shows a significant decongestant effect of the Sorbitol-containing Carragelose nasal spray in allergic rhinitis patients The product utilizes the effect of Sorbitol as treatment of a blocked nose without the side effect of habituation...
Marinomed Biotech AG
About the publication
16 February 2023 07:45AM
Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose
ATMARINOMED6
  Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose Major strategic developments in 2022 to boost future growth Preliminary revenues stable at € 11.3 m for 2022 (2021: € 11.6 m) despite lack of milestone payments in 2022 Adjusted for the milestone payment in 2021, underlying revenues have incr...
Marinomed Biotech AG
About the publication
More Marinomed Biotech AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN